MOLECULAR TARGETING TECHNOLOGIES, INC.

Translating Novel Technologies into Tomorrow's Medicines

^{177}Lu-DOTA-EBTATE

A long-lasting somatostatin analog

A potential best-in-class treatment for gastroenteropancreatic neuroendocrine tumors



Single Injections (3 months after 19.5 mCi)
Primary tumor reduced by 53% & liver metastasis reduced by 45%

EBTATE Improved PK/PD vs. Lutathera (Novartis)

EBTATE reached peak slower and had a prolonged plateau



EBTATE (blue) vs. Lutathera (red)

EBTATE showed 7.9-fold increase in tumor uptake vs. Lutathera



# of disintegrations of ^{177} Lu

MTTI obtained exclusive worldwide rights to EBTATE from NIH (invented by Drs. Xiaoyuan Chen and Orit Jacobsen)

Challenges

- GEP - NET incidence 5.8/100K
- Current treatments have limitations
- Lutathera response rate is 19%
- Multiple Lutathera doses cause kidney and bone toxicity

Solution

~80% of NETs overexpress somatostatin receptors. EBTATE was designed to extend in vivo half-live over Lutathera, increasing probability of binding to those receptors, enabling fewer, lower doses of the radiotherapeutic.

Technology

EBTATE incorporates Evans Blue in the somatostatin analog backbone which significantly increases residence in albumin, a virtual slow release system. Demonstrated negligible toxicity. Patent pending.

Proof of Concept

Extensive preclinical and two Phase I studies (50 patients) performed by NIH and Peking Union Medical College Hospital (China) show improved safety and efficacy.

Next

US Phase I & II trials 2020-23

MTTI

Molecular Targeting Technologies, Inc. is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases.

Two radiotherapeutics and two radiodiagnostics lead our 10 asset pipeline.

Contact: cpak@mtarget.com

More information: www.mtarget.com.